Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Privacy Policy
  • Contact US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Deals PIC

Liaocheng University and Shanghai Maiboxing Biotechnology Sign RMB 19 Million Pact to Co‑Develop LCUGZ1007 – Next‑Generation E‑PDC Probody Drug Conjugate

Fineline Cube Sep 8, 2026
Company Deals PIC

China Biotech’s Panboron BNCT Hospital Signs Strategic Pact with OncoCare Cancer Centre HK – Launching Cross‑Border BNCT Oncology Cooperation

Fineline Cube Sep 8, 2026
Company Deals PIC

Guangdong Taienkang Completes Capital Increase in Procapzoom – Secures Exclusive China Rights to World‑First Ocular Surface Cell Therapy SZ018

Fineline Cube Sep 8, 2026
Company Deals PIC

HepaBio Therapeutics Raises Series A Strategic Funding From TriApex to Advance Organoid Technology and Next‑Generation Drug R&D Systems

Fineline Cube Sep 7, 2026
Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Fineline Cube Sep 8, 2026
Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Fineline Cube Sep 8, 2026
Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Fineline Cube Sep 8, 2026
Company Drug

Sanofi’s Riliprubart Granted Orphan Drug Status for Antibody-Mediated Rejection Treatment

Fineline Cube Jun 26, 2025

France-based major Sanofi (NASDAQ: SNY) has secured Orphan Drug Designation (ODD) from the US Food...

Company Drug

Bio-Thera Solutions Initiates Phase III Trial of BAT8006 for Platinum-Resistant Ovarian Cancer

Fineline Cube Jun 26, 2025

Guangzhou-based Bio-Thera Solutions (SHA: 688177) announced the successful first patient dosing in its Phase III...

Company

AstraZeneca Restructures to Form Gastrointestinal Oncology Business Unit

Fineline Cube Jun 26, 2025

UK major AstraZeneca (AZ, NASDAQ: AZN) this week reportedly unveiled a new organizational restructuring plan,...

Company Drug

EMA Panel Recommends Brukinsa Tablet Formulation for Approval

Fineline Cube Jun 26, 2025

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...

Company Drug

Sinocelltech Wins NMPA Clearance for TriAb SCTB39G in Solid Tumors

Fineline Cube Jun 26, 2025

China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received clearance from the National...

Company Drug

CARsgen’s Satri-cel NDA Accepted by China’s NMPA for Gastric Adenocarcinoma

Fineline Cube Jun 26, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that the National Medical Products Administration (NMPA)...

Company Drug

Lepu Biopharma Gains EMA Approval for MRG003 HNSCC Clinical Trial

Fineline Cube Jun 26, 2025

China-based Lepu Biopharma Co., Ltd (HKG: 2157) announced that it has received approval from the...

Company Deals

RemeGen Inks Global Licensing Pact With Vor Biopharma for Telitacicept

Fineline Cube Jun 26, 2025

China-based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) announced an exclusive licensing agreement with U.S.-based...

Company Drug

Angel Pharma Gains NMPA Approval for Soquelitinib in Atopic Dermatitis Trial

Fineline Cube Jun 26, 2025

China-based Angel Pharmaceuticals Ltd announced that it has received approval from the National Medical Products...

Company Drug

Biogen’s Phase I Results Highlight Salanersen’s Potential in Spinal Muscular Atrophy

Fineline Cube Jun 26, 2025

Biogen (NASDAQ: BIIB) announced this week topline results from the Phase I study of salanersen...

Company Deals Drug

Kymera and Sanofi Advance IRAK4 Program With Selection of KT-485 for Clinical Development

Fineline Cube Jun 26, 2025

US-based Kymera Therapeutics Inc. (NASDAQ: KYMR) announced updates to its IRAK4-targeted program collaboration with Sanofi....

Company Drug

LG Chem’s Cross-Linked Sodium Hyaluronate Gel Gains NMPA Approval for Midface Use

Fineline Cube Jun 26, 2025

South Korea’s LG Chem announced that its cross-linked sodium hyaluronate gel with lidocaine has received...

Company Deals

Porton Advanced Partners With EVA Pharma to Boost CAR-T Cell Therapy in MENA

Fineline Cube Jun 26, 2025

China-based Contract Development and Manufacturing Organization (CDMO) Porton Advanced Solutions Ltd. has entered into a...

Company Drug

Eli Lilly’s Amyvid Sees FDA-Approved Label Update for Alzheimer’s Diagnosis

Fineline Cube Jun 26, 2025

US-based Eli Lilly & Co. (NYSE: LLY) announced the US Food and Drug Administration (FDA)...

Company Deals

Gilead Signs Licensing Pact With Kymera Therapeutics for CDK2-Targeted MGD

Fineline Cube Jun 26, 2025

US major Gilead Sciences, Inc. (NASDAQ: GILD) this week entered into an exclusive option and...

Company Drug

SineuGene’s ALS Gene Therapy SNUG01 Granted FDA Orphan Drug Designation

Fineline Cube Jun 26, 2025

Beijing-based SineuGene Therapeutics, a developer of gene therapies for brain disorders, announced this week that...

Company Drug

Acotec Scientific Wins NMPA Approval for Armoni-HP Balloon Catheter

Fineline Cube Jun 26, 2025

China-based Acotec Scientific Holdings Ltd (HKG: 6669) announced that it has received marketing approval from...

Company Deals

Immvira Bioscience Files for Hong Kong IPO to Advance Oncolytic Immunotherapy Pipeline

Fineline Cube Jun 26, 2025

Shenzhen-based Immvira Bioscience Inc. has filed for an initial public offering (IPO) with the Hong...

Company Drug

Genevector’s JWK002 Gains NMPA IND Approval for XLRS Gene Therapy

Fineline Cube Jun 26, 2025

China-based Chengdu Geneector Biotechnology Co., Ltd. (Genevector), a developer of AAV gene therapy drugs, announced...

Company Deals

CMS Plans Secondary Listing on Singapore Exchange to Enhance Shareholder Base and Liquidity

Fineline Cube Jun 25, 2025

China Medical System Holdings Ltd (CMS; HKG: 0867) announced its proposal for a secondary listing...

Posts pagination

1 … 188 189 190 … 717

Recent updates

  • Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management
  • Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform
  • METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker
  • Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent
  • Sun-Novo Pharmaceutical and DeepMed Technology Sign Strategic Pact on AI‑Driven Drug R&D – Building Closed‑Loop “AI Design + Wet‑Lab Validation” Discovery System
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Wins NMPA Clinical Trial Approval for SHR‑1179 – First‑in‑Class Biological Candidate for Weight Management

Company Drug

Hualan Bio Wins NMPA Clinical Trial Approval for Novel Influenza mRNA Vaccine – China’s Vaccine Major Pushes into mRNA Platform

Others

METiS Therapeutics Partners with Hengrui Pharma – Deploying AiTEM AI Formulation Platform at China’s Leading Drugmaker

Company Deals PIC

Suzhou AsiFlyer Biotechnology Secures Exclusive Worldwide License from ShanghaiTech University for AI‑Designed Recombinant Botulinum Toxin Patent

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.